How did Royalty Pharma perform in the third quarter of 2024?

Portfolio Receipts rose 15% to $735 million, Royalty Receipts rose 15% to $732 million, and net cash provided by operating activities was $704 million, up 23% from $574 million a year earlier. Adjusted EBITDA (non-GAAP) was $679 million and Portfolio Cash Flow (non-GAAP) was $617 million.

What changed in the company's 2024 financial guidance?

Portfolio Receipts guidance was raised to $2,750 million–$2,800 million from $2,700 million–$2,775 million. Expected Royalty Receipts growth is now 11% to 13%, up from 9% to 12%. Payments for operating and professional costs are now expected at about 8.5% of Portfolio Receipts, versus 8% to 9% previously. Interest paid guidance remains $160 million. The guidance excludes transactions announced after the release date.

How much capital did Royalty Pharma deploy and what transactions did it complete?

Capital Deployment was approximately $1.2 billion in the third quarter and $2.2 billion for the first nine months of 2024. Transactions included synthetic royalties on Syndax/Incyte's Niktimvo and Ascendis' Yorvipath, and a royalty on Pharvaris' deucrictibant. The company said it has announced up to approximately $2.7 billion of new transactions during 2024, including $350 million in November.

What is the company's balance sheet and liquidity position?

As of September 30, 2024, cash and cash equivalents were $950 million and total debt with principal value was $7.8 billion. Current portion of long-term debt was $997 million, and long-term debt net of current portion was $6,610 million. The company repurchased about seven million Class A shares for $180 million in the first nine months of 2024.

What did the filing say about the company's future interest costs?

Total interest paid for 2024 is anticipated to be approximately $160 million, with a de minimis amount expected in the fourth quarter. For 2025, interest paid is anticipated to be approximately $260 million, including interest on the $1.5 billion of notes issued in June 2024.

RPRX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) furnished an 8-K under Item 2.02 reporting results for the quarter ended September 30, 2024, via Exhibit 99.1.

Portfolio Receipts rose 15% to $735 million^a, Royalty Receipts rose 15% to $732 million, and net cash provided by operating activities was $704 million, up 23%. Adjusted EBITDA (non-GAAP) was $679 million and Portfolio Cash Flow (non-GAAP) was $617 million, each up 17%. Capital Deployment was approximately $1.2 billion in the quarter and $2.2 billion for the first nine months, and the company reported cash and cash equivalents of $950 million and total debt with principal value of $7.8 billion at September 30, 2024.

Management raised full-year 2024 Portfolio Receipts guidance to $2,750 million to $2,800 million^b, from $2,700 million to $2,775 million previously, with Royalty Receipts growth now expected at 11% to 13%, versus 9% to 12% before. The guidance excludes transactions announced after the release date. The company also repurchased approximately three million Class A ordinary shares for $95 million in the quarter, and stated 2024 interest paid is anticipated at about $160 million with approximately $260 million expected in 2025.

During the quarter the company added royalties on several therapies, including synthetic royalties on Niktimvo and Yorvipath and a royalty on deucrictibant in Phase 3 development. Management cited FDA approvals for Cobenfy, Tremfya for ulcerative colitis and Voranigo during the period. Net income attributable to Royalty Pharma plc was $544 million^c, compared with $72 million a year earlier, and the filing includes an Adjusted EBITDA and Portfolio Cash Flow reconciliation to GAAP.

02—Key points

Key Highlights

Portfolio Receipts increased 15% to $735 million in Q3 2024 from $637 million in Q3 2023, led by Trelegy, Evrysdi, the cystic fibrosis franchise and Tremfya.
Full-year 2024 Portfolio Receipts guidance raised to $2,750 million–$2,800 million from $2,700 million–$2,775 million; Royalty Receipts growth now expected at 11% to 13%.
Net cash provided by operating activities was $704 million, up 23% from $574 million; Portfolio Cash Flow (non-GAAP) was $617 million, up 17%.
Capital Deployment was approximately $1.2 billion in Q3 2024 and $2.2 billion for the first nine months of 2024, versus $1.2 billion for the first nine months of 2023.
Net income attributable to Royalty Pharma plc was $544 million in Q3 2024, compared with $72 million in Q3 2023, after a $228 million benefit from changes in expected cash flows from financial royalty assets.
Cash and cash equivalents were $950 million and total debt principal was $7.8 billion as of September 30, 2024; the company repurchased about $95 million of Class A shares in the quarter.
Recent deals included a $350 million upfront synthetic royalty on Niktimvo (November 2024) and a $150 million synthetic royalty on Yorvipath (September 2024).

03—Questions

Frequently Asked Questions

How did Royalty Pharma perform in the third quarter of 2024?
Portfolio Receipts rose 15% to $735 million, Royalty Receipts rose 15% to $732 million, and net cash provided by operating activities was $704 million, up 23% from $574 million a year earlier. Adjusted EBITDA (non-GAAP) was $679 million and Portfolio Cash Flow (non-GAAP) was $617 million.
What changed in the company's 2024 financial guidance?
Portfolio Receipts guidance was raised to $2,750 million–$2,800 million from $2,700 million–$2,775 million. Expected Royalty Receipts growth is now 11% to 13%, up from 9% to 12%. Payments for operating and professional costs are now expected at about 8.5% of Portfolio Receipts, versus 8% to 9% previously. Interest paid guidance remains $160 million. The guidance excludes transactions announced after the release date.
How much capital did Royalty Pharma deploy and what transactions did it complete?
Capital Deployment was approximately $1.2 billion in the third quarter and $2.2 billion for the first nine months of 2024. Transactions included synthetic royalties on Syndax/Incyte's Niktimvo and Ascendis' Yorvipath, and a royalty on Pharvaris' deucrictibant. The company said it has announced up to approximately $2.7 billion of new transactions during 2024, including $350 million in November.
What is the company's balance sheet and liquidity position?
As of September 30, 2024, cash and cash equivalents were $950 million and total debt with principal value was $7.8 billion. Current portion of long-term debt was $997 million, and long-term debt net of current portion was $6,610 million. The company repurchased about seven million Class A shares for $180 million in the first nine months of 2024.
What did the filing say about the company's future interest costs?
Total interest paid for 2024 is anticipated to be approximately $160 million, with a de minimis amount expected in the fourth quarter. For 2025, interest paid is anticipated to be approximately $260 million, including interest on the $1.5 billion of notes issued in June 2024.

04—Continue

← View all 8-K filings